CSU Animal Cancer Center Clinical Trial

Patient Disease:
Multiple myeloma in dogs.

Study Name:
Phase II, Open label trial of MBC-11 for the treatment of canine myeloma.

Purpose of the Study:
Multiple myeloma is an uncommon but uniformly fatal canine disease. While the majority of dogs will respond to chemotherapy utilizing standard cytotoxic agents as described in humans (e.g. melphalan, vincristine, doxorubicin), greater than 95% of dogs will relapse with chemotherapy-refractory disease. The median survival time is approximately 1.5 years from diagnosis.

Recent evidence suggests that the etidronate-AraC conjugate MBC-11 may have substantial antitumor and antiresorptive effects in mouse models of myeloma. However, conventional mouse subcutaneous xenografts may not accurately recapitulate the effect of MBC-11 on inhibition of myeloma progression. For this reason, clinical evaluation of MBC-11 will be performed in dogs with spontaneous myeloma.

Patient Entry Criteria:
Dogs with a confirmed diagnosis of multiple myeloma are eligible for this study. Dogs must undergo some diagnostic testing prior to starting the study to ensure that they are eligible. They must have good function of liver and kidneys, have acceptable blood cell counts, and are free of severe underlying disease. A three-week washout from chemotherapy and a 72-hour washout period from corticosteroids is required prior to enrollment.

Owner Responsibilities:
Owners are responsible for the cost of diagnosing the dog's myeloma prior to entering the study. The owner is expected to make and keep all appointments according to the study protocol, and must be committed to completing the entire study protocol and follow-up examinations.

Financial Incentives:
Clients participating in this study will be given special financial considerations. Specifically, all costs related to the study are covered, and the owner will receive a $1000 credit to their account at the completion of the study.

If you have further questions about any of our clinical trials, please complete an online consult request form below or call or Oncology Clinical Coordinator at (970) 297-4068.